Reuters logo
4 years ago
Royalty Pharma says Elan sale process seeks to deflect Royalty bid
June 14, 2013 / 2:55 PM / 4 years ago

Royalty Pharma says Elan sale process seeks to deflect Royalty bid

(Reuters) - Royalty Pharma believes that the only reason Elan Corp Plc ELN.I has announced a sales process is to deflect Royalty's own offer, the company's CEO said in a statement Friday morning.

Royalty Pharma has not heard from Elan or its financial advisers, said Pablo Legorreta, Royalty's chief executive officer, in the e-mailed statement.

"If shareholders want to have the option to choose between Royalty Pharma's offer or a sale process, they should vote against all four of Elan's proposals, especially the share repurchase program," the firm said in its statement.

Reporting By Jessica Toonkel; Editing by Gerald E. McCormick

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below